The Principal Investigator of the ResIn study from October 2015 will be Dr Stuart Clarke (Southampton). Co-applicants are Michael Head (University of Southampton), Joseph Fitchett (Harvard School of Public Health), Rifat Atun (Harvard School of Public Health), Marie-Louise Newell (University of Southampton), and Anthony Scott (London School of Hygiene and Tropical Medicine). Michael Head is the senior research fellow (and project lead) and Becky Brown is the project research fellow.
Dr Stuart Clarke
Stuart is PI on the ResIn grant. Dr Clarke developed his independent research career in 1999 when he was Director of the Scottish Meningococcus and Pneumococcus Reference Laboratory. His research focuses on the molecular epidemiology of Streptococcus pneumoniae and other vaccine-preventable bacterial infections, particularly in relation to polysaccharide conjugate vaccines. Dr Clarke was involved in the national meningococcal carriage study, led by Professors Martin Maiden and James Stuart, which was mainly funded by the Wellcome Trust. His laboratory led on the Scottish component of the study jointly with Health Protection Scotland. His laboratory was the first to introduce automated methods for multi-locus sequence typing (MLST) and was also the first reference laboratory in the world to introduce the method as a routine clinical service. He has since been involved in various pneumococcal and MenB carriage studies. The Southampton paediatric pneumococcal carriage study has been running for 10 years, since the introduction of pneumococcal conjugate vaccines in the UK.
In collaboration with a pharmaceutical company, Dr Clarke leads the microbiology component of a 5 year programme of work which aims to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD (AECOPD) episodes. Dr Clarke has many other international collaborations, mostly in South East Asia. In Singapore, he collaborates with Professor Martin Hibberd and Dr Swaine Chen at the A*Star Genome Institute Singapore and also with colleagues in the Department of Microbiology at the National University of Singapore where he holds an Adjunct Associate Professor position.
Stuart obtained a PhD in Molecular Microbiology at the University of Leicester. He was Director of the Scottish Meningococcus and Pneumococcus Reference Laboratory in Glasgow between 1998 and 2004. He then took up specialist training in public health in Hampshire and was awarded an MSc in Public Health from the London School of Hygiene and Tropical Medicine in 2005. He became a Fellow of the Royal College of Pathologists and a Fellow of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom in 2007.
Dr Clarke is Reader in Infectious Disease Epidemiology and Honorary Consultant in Health Protection. He splits his time between the University of Southampton Faculty of Medicine and Health Protection Agency Microbiology Services Southampton. He has published more than 80 peer-reviewed papers in the areas mainly in the field of N. meningitidis and S. pneumoniae infection. His current work focuses on the epidemiology of pneumococcal carriage and disease in relation to polysaccharide conjugate vaccines.
Dr Michael Head
Michael Head is a Senior Research Fellow based in the Faculty of Medicine and the Global Health Research Institute at University of Southampton. He joined Southampton is October 2015, and prior to this was at University College London for eleven years and retains a visiting position at UCL, in the Farr Institute for Health Informatics. He is co-founder of the ResIn study and has been involved in leading work on mapping infectious disease research investments since 2006 (initially via the Infectious Disease Research Network). He has developed and refined the methodology surrounding the data collection, categorisation of studies and presentation of results. He is lead author on most of the study’s many peer-reviewed outputs and has invited to give many lectures on this work at national and international conferences and seminars, including speaking for the Royal Society of Medicine Global Health Alerts series in November 2012. He was manager of the Infectious Disease Research Network (IDRN) since 2004 and has developed and maintained their highly-accessed website (over 60,000 hits each year for the last five years). Through the IDRN, he has excellent links and broad knowledge of the infectious disease research community, and has authored several influential reports on IDRN outputs and priority topics. He has completed a PhD by published works (using the ResIn outputs) at the University of Amsterdam and the Amsterdam Institute of Global Health, has studied epidemiology to postgraduate level at the London School of Hygiene and Tropical Medicine, and has also trained in global health, systematic reviews, health policy and data linkage. He has research interests in care homes and infectious disease (especially scabies), and also public engagement (he is a regular speaker on the subject of vaccinations and ‘anti-vaxxers’ at Skeptics in the Pub meetings around the UK, and has taken this talk into secondary schools).
Dr Rebecca Brown
Rebecca Brown is a Research Fellow for the ResIn study based in the Faculty of Medicine at the University of Southampton. In 2011, she received a BSc in Biochemistry from the University of Manchester following which she went on to be awarded an MSc in Immunology from Imperial College, London in 2012. She has completed her PhD in Clinical Microbiology at Cardiff University during which she has worked closely with Public Health England to monitor epidemiology of Mycoplasma pneumoniae infections, and to develop diagnostics and molecular typing methods for human Mycoplasma species.
Dr Joseph Fitchett
Dr Joseph Fitchett is a Frank Knox Fellow in public health and infectious disease epidemiology, focusing on the impact of global policy on vaccines, drugs, and access to heath technologies.
In particular, Joe’s work has focused on vaccines for emerging infections, drugs for neglected diseases, and the intersection between the TB and HIV epidemics. Joe is a co-founder of the ResIn study and also a collaborator with the Global Burden of Disease study.
Prof Rifat Atun
Professor Rifat Atun is Professor of Global Health Systems at Harvard School of Public Health, MA, USA. He has many years of research experience in global health financing and has published widely in high-impact journals in this area. In 2008-12 he was a member of the Executive Management Team of The Global Fund to Fight AIDS, Tuberculosis and Malaria as the Director of Strategy, Performance and Evaluation Cluster. He chaired the panel that made annual funding recommendations of US$ 2-2.5 billion and hence was able to gain unique insight into how investment decisions are made and how they drive the formulation of policy for infectious diseases.
Prof Marie-Louise Newell
Marie-Louise Newell is Professor of Global Health and has a background in Medicine, Demography and Epidemiology; her research has focused on maternal and child health, particularly infections and transmission from mother-to-child. At the University College London Institute of Child Health, she led a European cohort of HIV-infected pregnant women and their children, and was involved in research in developing countries, particularly in sub-Saharan Africa. Since late 2005 for eight years, she has been based in rural KwaZulu-Natal, South Africa as Director of the Wellcome Trust-funded Africa Centre for Health & Population Studies, University of KwaZulu-Natal where she has initiated a broad innovative programme of research addressing the impact of HIV infection at a population, household and individual level. She established a partnership with the SA Department of Health in the Hlabisa sub-district to provide HIV treatment and care, resulting in more than 28,500 HIV-infected people initiated on treatment by mid-2013. Recent research from the Centre has shown that the HIV treatment provided in the public programme has resulted in a substantial reduction of adult and child mortality, and has started to have an impact on HIV incidence. However, with success also comes concern: her interest in infections in pregnant women and their children is now moving to evaluating the mid- and longer term implications of exposure to infections and treatment for the woman and her child. She reviews for a large number of expert journals, is member of international expert review bodies and was appointed a Fellow of the UK Academy of Medical Sciences in 2012 and a Fellow of the University of KwaZulu-Natal in 2013.
Now at Southampton, she is focusing on research on the mid- and longer term consequences of exposure to HIV and its treatment in fetal and early life for children born to HIV infected mothers, as well as continue to evaluate HIV prevention interventions. Marie-Louise is also leading on the development of a Global Health Research Institute at Southampton.
Prof Anthony Scott
Anthony trained in clinical infectious diseases and epidemiology before moving to the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya in 1993. He has spent most of the last 20 years in Kenya, studying pneumococcal disease and pneumonia in children and adults, and vaccines to prevent them. Anthony is a Wellcome Trust Senior Research Fellow in Clinical Science and works in clinical paediatrics in Kilifi. He joined the School in January 2013 after 15 years based at Oxford University. In addition to his research he has developed a surveillance network for invasive bacterial diseases in East Africa (Netspear) and co-directs the Kilifi Health and Demographic Surveillance System. Anthony works frequently with WHO and GAVI on vaccine preventable diseases and with the Ministry of Health in Kenya on the evaluation of pneumococcal vaccine. In the UK he is a member of the Joint Committee on Vaccination and Immunisation (JCVI) and Director of the the NIHR Health Protection Research Unit in Immunisation at LSHTM which involves a portfolio of work on disease burden, vaccine effectiveness, vaccine safety, modelling, cost-effectiveness, vaccine acceptability and policy implementation in collaboration with Public Health England.
Anthony’s main research interests are in child health and vaccines in East Africa. He runs the Pneumcoccal Conjugate Vaccine Impact Study, an effectiveness evaluation of vaccine introduction in Kenya, and a series of associated studies of transmission and modelling of pneumococcal disease, evaluation of vaccine safety, and pathogen population structure.
Additional or previous collaborators
Amos is a Masters of Public Health student at the Harvard School of Public Health, and is in his final year of M.D. studies at the University of Massachusetts Medical School. He began working with the ResIn study in 2014, while studying under Dr. Rifat Atun at HSPH. He completed his Sc.B. in neuroscience at Brown University, and also has been involved epidemiological research and systematic reviews.
Damilola Soyode is currently a Master of Public Health student at Harvard School of Public Health focusing on global health and an M.D. candidate in her final year at the University of California, San Diego School of Medicine. She received a BSc in biology from Imperial College London, UK where she concentrated on infectious agents and epidemiology. She became part of the ResIn study in 2014.
Jimena Villar de Onis is a Masters in Science in Public Health candidate at the Harvard of Public Health, focusing on global health, disaster relief, and failing health systems in countries dealing with humanitarian disasters. She graduated in 2010 from the University of Edinburgh with a degree in Law with honours where she studied human rights and the interface of public health and the law. Jimena joined the ResIn study in 2014 to explore global funding on Ebola.
Vaitehi is currently a final year medical student at Imperial College London. She completed her BSc in Immunity and Infectious Diseases in 2013. She is a member of Universities Allied for Essential Medicines (UAEM), and as such is particularly interested in the role of universities in infectious disease research.
Charlie Zhou is a final year medical student at the University of Oxford. He received a BA in Pathology in 2013 from the University of Cambridge, specializing in cancer and virology. He joined the ResIn study in 2014 to help delineate research funding towards oncology in the UK.